CD4 and non-small cell lung carcinoma: Therefore, we sought to identify and investigate the frequency and functional activity of the CD4+ Treg subtypes, in NSCLC patients, particularly of three distinct circulating CD4+ Treg subtypes (naive, effector and terminal effector).